Medpace Holdings Inc vs Twilio Inc — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while Twilio Inc trades at $289.47 (market cap $42.35B). The key difference: Twilio Inc is far larger — about 2.5× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is more actively traded (223,093 versus 1,862,642). Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Twilio Inc for 56 Days on average.
| MEDP | TWLO | |
|---|---|---|
Market Cap | $16.82B | $42.35B |
Volume | 223,093 | 1,862,642 |
Sector | Health | Technology |
52-Week High | $630.19 | $301.27 |
52-Week Low | $393.42 | $106.23 |
Typical Hold Time | 14 Days | 56 Days |
Enterprise Value | $16.44B | $40.76B |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
Twilio (TWLO) trades at $275.77, up 1.01% with a bullish technical signal. The company shows strong fundamental improvement with revenue growing from $3.8B in 2022 to $5.1B in 2025, achieving positive net income of $34M after years of losses. Recent Q2 2026 earnings beat expectations with EPS of $1.47 versus $1.32 expected. The stock's inclusion in the S&P 500 index effective October 6, 2026, provides institutional validation and potential index fund inflows.
Twilio presents a compelling growth story with accelerating revenue and profitability, though valuation remains elevated at P/E 38.09. Key risks include competitive pressures in customer engagement software and execution challenges in maintaining growth momentum. Analyst consensus remains strongly bullish with 77% buy ratings, though the current price exceeds the $254.65 consensus target, suggesting near-term caution may be warranted despite positive long-term prospects.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →